Strategic Acquisition Inform Diagnostics is part of Fulgent Genetics, with a recent acquisition history that signals potential for integration-friendly selling points, cross-sell opportunities for pathology services, and shared technology platforms that can streamline purchasing cycles.

Laboratory Scale State-of-the-art labs in Boston and Dallas indicate robust capabilities and capacity to handle high-volume pathology workflows, enabling sell-in for scalable services, automated reporting, and enterprise-level SLAs to larger health systems.

Digital Readiness Tech stack includes Kubernetes, OneTrust, Microsoft 365, and monitoring tools, suggesting a mature IT environment suitable for selling complementary software, data security enhancements, workflow automation, and integration with health information systems.

Clinical Reach Focused specialties in dermatopathology, gastrointestinal, neuropathology, breast, and genitourinary pathology offer targeted upsell opportunities to multispecialty practices, health systems, and integrated delivery networks seeking consolidated pathology services.

Compliance & Security Presence of governance and security tooling (OneTrust, KnowBe4, Nagios) alongside past whistleblower and litigation notes highlights a buyer preference for strong compliance, risk management, and cybersecurity capabilities when evaluating vendor partnerships.